TRVI
Trevi TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
If Trevi secures positive clinical signals and extends runway without heavy dilution, shares could re-rate toward small-cap biotech multiples driven by program value and potential partnerships.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -2.6.
What can break
Failed trials, negative safety signals, or dilutive financings could drive the equity toward zero; cash runway and binary readouts are main downside drivers.
Momentum
82
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.61 · Bull $1.22 · Bear $0.30
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-29 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $21.50
Why
Momentum82 · Δ7d -2.6
Value41 · Δ7d +0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
82
34% active weight
Current posture
7d trendFlat
Δ7d
-2.6
Δ21d
-2.2
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
0
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade D. Momentum 81.8 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$1.92B
Beta
0.96
Shares Out
128.23M
P/E (TTM) · Derived
-31.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-42.36
Rev YoY
-
EPS YoY
+37.8%
Gross Margin
-
Op Margin
-
Net Debt
-$107.59M
Current Ratio
21.93
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology